Review

Intracoronary acetylcholine application as a possible probe inducing J waves in patients with early repolarization syndrome

Toru Maruyama, M.D., Ph.D.*', Kazumasa Fujita, M.D., Kei Irie, M.D., Shouhei Moriyama, M.D., Mitsuhiro Fukata, M.D., Ph.D.

Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Higashi-ku, Maidashi 3-1-1, Fukuoka 812-8582, Japan

A R T I C L E   I N F O

Article history:
Received 7 November 2016
Received in revised form 18 December 2016
Accepted 27 December 2016
Available online 6 February 2017

Keywords:
Acetylcholine
Early repolarization syndrome
J waves
Vasospastic angina

A B S T R A C T

Acetylcholine is widely used for a diagnostic provocation test of coronary spasm in patients with vasospastic angina. Acetylcholine usually induces coronary vasodilatation mediated by muscarinic receptor activation, but sometimes it evokes vasoconstriction of coronary arteries where the endothelium is damaged. Early repolarization syndrome is characterized by a J wave observed at the end of the QRS complex in a surface electrocardiogram. The J wave is attributed to the transmural voltage gradient at the early repolarization phase across the ventricular wall, which stems mainly from prominent transient outward current in the epicardium, but not in the endocardium. Transient high-dose application of acetylcholine into the epicardial coronary arteries provides a unique opportunity to augment net outward current, selectively, in the ventricular epicardium and unmask the J wave, irrespective of the cardiac ischemia based on coronary spasm. Acetylcholine augments cardiac membrane potassium conductance by enhancing acetylcholine-activated potassium current directly and by activating adenosine triphosphate-sensitive potassium current, in addition to the reduced sodium and calcium currents in the setting of severe ischemia due to vasospasm. However, the role of acetylcholine as an arrhythmogenic probe of the J wave induction in patients with suspected early repolarization syndrome warrants future prospective study.

© 2017 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Contents

1. Introduction .......................................................................................................................... 424
2. Discussion ............................................................................................................................ 425
   2.1. ACh and coronary spasm provocation test ...................................................................... 425
   2.2. Cardiac ischemia and early repolarization syndrome (ERS). .......................................... 425
   2.3. J wave and ERS .............................................................................................................. 426
   2.4. Brugada syndrome and ERS .......................................................................................... 426
   2.5. ACh and the J wave ....................................................................................................... 426
   2.6. Mechanistic consideration ............................................................................................. 427
3. Conclusions .......................................................................................................................... 428
Disclosures ................................................................................................................................ 428
Conflict of interest .................................................................................................................... 428
Acknowledgments ..................................................................................................................... 428
References .................................................................................................................................... 428

1. Introduction

In the last century, intracoronary application of acetylcholine (ACh) was established as a diagnostic provocation test of coronary
spasm in patients with suspected vasospastic angina. Because the effects of ACh is short-lived, this provocation test can evaluate the direct effects of high-dose ACh on vasomotion in the epicardial coronary arteries. Vasospasm is considered to be the dysregulation of endothelium controlling vasomotion, inappropriate hypercontractility of vascular smooth muscle, or both [1]. ACh yields endothelium-dependent muscarinic vasodilation in normal coronary arteries, whereas it induces vasoconstriction in coronary arteries with endothelial injury [2]. Since autonomic regulation involves arrhythmogenesis as well as coronary vasomotor tonus, intracoronary high-dose application of short-lived ACh may have a key role, not only in the diagnostic provocation test of coronary vasospasm, but also in the arrhythmogenesis by cholinergic electrophysiological actions, irrespective of the association with severe cardiac ischemia due to coronary spasm.

2. Discussion

2.1. ACh and coronary spasm provocation test

ACh, a neurotransmitter of the parasympathetic nervous system, is inactivated quickly by circulating cholinesterase, and is effective for only a very short period when applied by intracoronary injection. Vasomotor function is regulated by the balance between the endothelium-derived contracting factors (thromboxane A2, leukotrienes, and others) and the relaxing factor of nitric oxide (NO). ACh disrupts the intrinsic balance of endothelium-derived opposing factors leading to the focal or diffuse coronary spasm at the site, releasing insufficient NO [3]. This property is utilized widely in coronary angiography to evoke coronary spasm for diagnosis of vasospastic angina.

Although the spasm provocation test using ACh is regarded as a safe and reliable technique to diagnose vasospastic angina, arrhythmogenic complications are not unusual. Consequently, the Japanese Circulation Society guideline recommends temporary pacemaker lead insertion during ACh application to reverse transient bradycardia and atrioventricular block based on parasympathetic activation [4]. Paroxysmal atrial fibrillation (AF) is also ascribed to the cholinergic effects of ACh on the atria, where ACh-activated potassium (K+)-channel currents are abundant. The activation of ACh-activated K+ current (I_{K,ACH}) reduces atrial refractoriness heterogeneously, which underlies focal ectopic activities triggering AF and multiple reentries sustaining AF [5,6]. Sueda and Kohno have reported more serious complications of this provocation test [7]. They concluded that ventricular tachycardia and/or fibrillation (VT/VF), observed during the intracoronary application of ACh, occurred more frequently than with the intracoronary injection of ergonovine, and that VT/VF occurred more frequently in Asian patients than in Western patients undergoing the ACh application test. Although spasminduced myocardial ischemia is the main underlying cause of serious complications, such as cardiogenic shock and severe hypotension associated with VT/VF, the exact etiology of the VT/VF observed in the ACh provocation test remains to be determined.

2.2. Cardiac ischemia and early repolarization syndrome (ERS)

ACh was originally applied for the diagnostic provocation test of coronary spasm in patients with suspected vasospastic angina [2]. Coronary vasospasm results in severe cardiac ischemia by profound reduction of major epicardial coronary flow and evident ST segment elevation on a surface electrocardiogram (ECG). The relationship between ERS and vasospastic angina has been drawing increasing attention, since the J wave is sometimes observed immediately before the onset of VT/VF in patients with vasospastic angina and acute myocardial infarction (AMI) [8-12]. Acute cardiac ischemia is accompanied by marked reduction of oxygen supply, tissue acidosis, accumulation of ischemic metabolites, and subsequent electrophysiological and electrocardiographic derangements [13]. Cardiac repolarization is accelerated by the sum of reduced inward sodium (Na+) and calcium (Ca2+) currents (I_{Na} and I_{Ca}) and augmented various outward K+ currents, which is heterogeneous, because of the differential sensitivity to ischemia between the epicardium and endocardium [14,15].

VT/VF, observed in ERS during ischemic events, are considered to be because of regionally different ischemic sensitivity, leading to phase 2 reentry. When considering that transient outward current (I_{to}) is a major ionic current responsible for J wave formation, in 1988, Litovsky and Antzelevitch reported that epicardial I_{to} is prominent relative to endocardial I_{to} [16]. Thereafter, the ventricular wall was recognized as being heterogeneous with respect to the I_{to} channel expression, density, and I_{to}-mediated epicardial phase 1 magnitude [17-19]. Moreover, epicardial I_{to} is suspected to be more sensitive to ischemia compared with the endocardial I_{to}. In 1993, Lukas and Antzelevitch investigated this regionally different sensitivity of I_{to} to ischemia in canine hearts [14]. They demonstrated that the action potential (AP) plateau was abolished in the epicardium but not abolished in the endocardium by simulated ischemia (hypoxic and acidic conditions with high K+ concentration) and that 4-aminopiridine restored the epicardial AP plateau. I_{to} is sensitive to 4-aminopiridine, and is a major time-dependent, voltage-sensitive current responsible for early repolarization. Conversely, there are ligand-gated, time-independent outward K+ currents. Intracellular adenosine triphosphate (ATP) has a ligand action to inhibit ATP-sensitive K+ channel current (I_{K,ATP}). I_{K,ATP} is activated by severe ischemia associated with intracellular ATP depletion, leading to AP shortening and extracellular K+ accumulation [20]. Pharmacological modulation of I_{K,ATP} affects the canine epicardial, but not the endocardial, AP repolarization, development of phase 2 reentry, and lethal ventricular arrhythmia, i.e., I_{K,ATP} activation by pinacidil promotes, whereas I_{K,ATP} inhibition by glibenclamide suppresses, these electrophysiological findings in canine ventricular tissues. These results indicate that I_{K,ATP} shows regionally different sensitivity to ischemia and plays a crucial role in the ischemic J wave formation and subsequent occurrence of VT/VF [21]. Identification of patients at risk of ischemic VT/VF is important. Arrhythmogenic vulnerability in the setting of AMI may be associated with a genetic predisposition, leading to the heterogeneous excitability, refractoriness, and conduction, which are based on depolarization and/or repolarization abnormalities [22].

2.3. J wave and ERS

ERS is characterized by J point elevation on surface ECGs, and the J wave is characterized by dynamic morphological changes that show a hump, notch, or slur at the end of the QRS complex on surface ECGs. Global prevalence of the J wave in the general population varies widely from 0.9% to 24.8% [23], which depends on the ethnicity, age, gender, and the diagnostic criteria of the J wave itself. ERS was formerly considered a normal benign repolarization variant, but the cumulative evidence, since 2008, indicates that ERS contains a possible risk of lethal VT/VF and sudden cardiac death (SCD) [24].

The Shanghai score system for diagnosis of ERS was proposed by the expert consensus conference [25]. Based on this proposal, patients with ERS, showing dynamic changes of J point elevation, followed by descending ST segment, observed in inferior leads, associated with short-coupled premature ventricular beats (PVBs), are considered to be in a high-risk group. Patients showing bradycardia-dependent J waves also have a poor prognosis,
2.4. Brugada syndrome and ERS

Brugada syndrome (BrS) was first reported in 1992 by Brugada and Brugada [28] in a multicenter report. Electrocardiographic manifestations of BrS were described originally as right bundle branch block and persistent ST segment elevation. However, these characteristic features are interpreted today as an early repolarization pattern, observed particularly in the anterior right ventricular outflow tract region [25]. Moreover, patients with BrS, associated with inferolateral early repolarization pattern show a higher risk of VT/VF, indicating that BrS, in addition to inferolateral early repolarization, reflects extensive J wave manifestations, leading to an electrical storm [29–31]. BrS and ERS are related manifestations in a broader spectrum of J wave syndromes, i.e., primary electrical disorders without structural heart diseases [25].

BrS and ERS show common features of inherited channelopathy, pathophysiological mechanisms causing VT/VF, and therapeutic effectiveness of pharmacological and non-pharmacological options. Both syndromes show ischemic ST elevation, male predominance, and evident vagal influences [32]. The magnitude of ST elevation and the occurrence of VT/VF in patients with BrS and ERS are generally dependent on heart rate [33] and frequently observed at night, with a full stomach or when vomiting [34–36]. Vagal dominance in the genesis of VT/VF in these patients is also reported in clinical studies using heart rate variability [37] and other autonomic function tests [38]. These syndromes are associated with mutations or rare variants of genes encoding channel proteins of K<sub>ATP</sub>, I<sub>Na</sub>, or I<sub>Ca</sub> which result in the gain of function in K<sub>ATP</sub> or the loss of function in I<sub>Na</sub> and I<sub>Ca</sub>. With respect to therapeutic options, isoproterenol infusion is emerging as a promising pharmacological intervention. Quinidine and bepridil are effective as conservative pharmacological treatments. Implantable cardioverter-defibrillators (ICDs) should be considered in cases presenting with drug-refractory VT/VF. These pharmacological and non-pharmacological modalities are common therapeutic strategies in treatment of J wave syndromes.

However, there are some differences between the J wave syndromes when comparing the provocation test and long-term prevention of arrhythmic events. Diagnostic tools for BrS are not necessarily helpful in ERS, since BrS is unmasked on surface ECG by using a class lc antiarrhythmic agent, which is a potent blocker of I<sub>Na</sub>. In Japan, pilocarpine is an example of a class lc agent widely used for diagnostic testing for suspected BrS. However, class lc agents tend to mask J waves in ERS, partly because of the QRS widening based on the ventricular conduction slowing [25]. Therefore, pharmacological probes to evoke persistent J waves have not yet been established. Antiarrhythmic effects of marine-derived ω-3 fatty acids, such as eicosapentaenoic acid (EPA), on ERS are reported in Japan. Hisamatsu et al. investigated the preventive effects of ω-3 fatty acid intake on cardiac death in community-dwelling men, without baseline cardiac diseases, in a prospective study. They concluded that risk of cardiac death associated with ERS might be attenuated by dietary intake of ω-3 fatty acid [39]. Endo et al. also investigated the relationship between serum EPA concentration and ERS in patients with AMI undergoing percutaneous coronary intervention. They demonstrated that J wave appearance and arrhythmic events were more frequent in patients with low serum EPA and suggested that the J wave is linked to low EPA in patients with AMI associated with ischemic VT/VF [40]. However, such favorable effects of EPA on BrS have not yet been reported.

2.5. Ach and the J wave

Screening out small groups of high-risk patients with ERS from the vast majority of those in the low-risk group of ERS and then giving appropriate therapy with an ICD to the limited high-risk patients, is essential to prevent SCD caused by VF/VT. For this purpose, use of pharmacological agents for diagnostic J wave induction is required. Kodama et al. reported a case of aborted SCD presenting with a de novo J wave by a coronary spasm provocation test using Ach [41]. A 51-year-old man experienced a cardiac arrest during a winter full marathon. He underwent bystander cardiopulmonary resuscitation and he was rescued without the use of an automated external defibrillator (AED). Vasospastic angina was suspected, and no structural heart diseases were found by routine noninvasive cardiac examinations after referral.

During left coronary infusion of Ach, this patient did not complain of chest pain, and coronary angiography demonstrated no spastic findings. The surface ECG demonstrated no discernible ST-T changes but distinct J waves in the inferior leads (Fig. 1). Short-coupled repetitive PVBs (Fig. 1) and the gradual appearance of J waves (Fig. 2) were observed during an increase in Ach dose from 10 to 100 μg. Since there was no evidence of coronary spasm in this case, dose-dependent effects of Ach on surface ECG findings are presumably based on the direct pharmacological actions of Ach, but not mediated by cardiac ischemia. In ambulatory monitoring performed after the Ach application test, nocturnal appearance of the J waves and their disappearance in the early morning were consistent with the cholinergic actions of Ach (Fig. 3). Although no evidence for life-threatening arrhythmia was found, Ach-induced coupllet premature ventricular beats (PVBs), as
preferential activation of epicardial, but not endocardial, ischemic sensitivity across the ventricular wall is attributed to the ECG J wave appearance is associated with ST elevation and that these those showing no J waves in the baseline ECG. They concluded that patients with vasospastic angina presenting with J waves, with Sato et al. come of the provocation test of coronary vasospasm using ACh. greater sensitivity of the epicardium to ischemia[14,15]. Different based on the accelerated epicardial repolarization because of the 2.6. Mechanistic consideration J waves are currently recognized as a surface ECG manifestation of the transmural voltage gradient of epicardial, in contrast to endocardial, ventricular AP at the early repolarization phase (phase 1) [25]. At that moment, the transmural voltage gradient is augmented by a distinct epicardial AP notch, caused by activation of $I_{K-ACh}$. ACh is considered to evoke J waves irrespective of the outcome of the provocation test of coronary vasospasm using ACh. An example of a positive case of the ACh application test was Sato et al.’s investigation of ischemic J wave dynamics in relation to ST segment changes [42]. They compared the VF occurrence in patients with vasospastic angina presenting with J waves, with those showing no J waves in the baseline ECG. They concluded that J wave appearance is associated with ST elevation and that these ECG findings are a sign of ischemic VF. The ischemic J wave is based on the accelerated epicardial repolarization because of the greater sensitivity of the epicardium to ischemia [14,15]. Different ischemic sensitivity across the ventricular wall is attributed to the preferential activation of epicardial, but not endocardial, $I_{K-ATP}$ [21]. In addition to the transmural difference, there is also an inferolateral difference, i.e., inferior $I_{Na}$ density is greater than lateral $I_{Na}$ density [27], which is compatible with the fact that J waves are observed particularly in inferior leads, indicating a high risk of VF in patients with vasospastic angina [12,25,27]. In acute ischemia, inward currents are suppressed, i.e., tissue acidosis inhibits $I_{Ca}$, and interstitial K$^+$ accumulation inactivates $I_{Kr}$ [13], which also promotes an outward shift in balance of the net transmembrane ionic currents.

Even in a negative provocation test, ACh increases membrane K$^+$ conductance by enhancing $I_{K-ACh}$, which is abundant in the atria but is also found in the ventricles. Koumi and Wasserstrom demonstrated that human ventricular $I_{K-ACh}$ shows channel conductance and kinetics similar to those in human atrial $I_{K-ACh}$, but that ventricular $I_{K-ACh}$ (concentration of ACh at half-maximal stimulation ($K_0)=0.13 \, \mu M$) is less sensitive to ACh relative to atrial $I_{K-ACh}$ ($K_0=0.03 \, \mu M$) [43]. Activation of $I_{K-ACh}$ contributes to the net outward current augmentation that produces the epicardial AP notch and J wave formation. Furthermore, ACh increases parasymptomatic tone by exerting cholinergic actions, which include negative chronotropism, which leads to a bradycardia-dependent J wave appearance [44]. ACh-induced muscarinic receptor activation inhibits inward $I_{Ca}$ [45]. These direct actions of ACh shift the net transmembrane ionic current balance toward the outward direction. Koncz et al. established the aerobic ERS model of coronary-perfused canine heart preparation using pilscainide ($I_{Na}$ blocker), pinacidil ($I_{K-ATP}$ opener), verapamil ($I_{Ca}$ blocker), and ACh as a cholinergic agent [27]. BrS shares some characteristic features of inherited channelopathy with ERS. Van and Antzelevitch [46] actually demonstrated ACh-induced epicardial AP dome depression and ST elevation in an arterially perfused myocardial wedge preparation as an experimental model of BrS (Fig. 4). Noda et al. reported that, clinically, right, but not left, coronary ACh infusion observed in Fig. 1, are considered as a cause of the aborted SCD in this patient with a resuscitation history.

Fig. 2. Electrocardiogram (ECG) during the coronary spasm provocation test using acetylcholine (ACh). A persistent J wave was shown in lead II, whereas gradual fragmentation of the QRS complex and clear J wave formation were observed in lead III under the application of the maximum dose (100 μg) of ACh. The minimal amplitude of the S wave in lead I was not augmented according to the appearance of the J wave in lead III, indicating that this surface ECG does not indicate that a right bundle branch block was caused by ACh.

Fig. 3. Ambulatory electrocardiogram monitoring indicates nocturnal appearance of a J wave at the end of the QRS complex (arrows), associated with a transient sinoatrial conduction block recorded at 23:46 pm (A), and disappearance of the J wave in the early morning at 6:55 am (B), at the equivalent baseline heart rate, i.e., minimum RR interval in A is 1240 ms, and basic RR interval in B is 1160 ms.

Fig. 4. In arterially perfused canine myocardial wedge preparations (A), acetylcholine (ACh) (3 μm/L) reduces dome amplitude in the epicardial action potential (AP) and elevates the ST segment in a transmural electrocardiogram (ECG). In another preparation (B), flecainide (7 μm/L), a potent Na channel blocker, is applied. Thereafter ACh (2 μm/L) causes loss of the AP dome in the epicardium, but not in the endocardium, and ST segment elevation in a transmural ECG under the presence of flecainide. Isoproterenol (0.5 μm/L) restores these epicardial AP configurations and ECG changes [46].
tends to elevate ST segment in the right precordial leads, without evidence of coronary spasm under the cumulative intra-coronary application of ACh [39]. However, a prospective cohort of laboratories, is required to strengthen the conceptual framework (Fig. 5) regarding the hypothetical ACh challenge test of ERS.

3. Conclusions

In addition to coronary vasomotor regulation, the pathophysiological mechanisms of J wave manifestation on surface ECGs were reviewed by focusing on the electrophysiology and basic pharmacology of ACh, which may have a role as a potential diagnostic probe of J wave syndromes. ACh unmasks the J waves; this is mediated by $I_{\text{K,ATP}}$ activation in ischemic conditions and by direct cholinergic effects of ACh on $I_{\text{K-ACh}}$ activation in non-ischemic conditions. These ligand-gated K⁺ channel activations increase background K⁺ conductance and shift the balance of epicardial transmembrane ionic currents toward the outward direction. There may be intermediate conditions between the distinct ischemic and non-ischemic states, where heterogeneous epicardial augmentation of $I_{\text{K,ATP}}$ in addition to reduced $I_{\text{Ca}}$ and $I_{\text{Na}}$ might be the persistent underlying substrate of the J wave syndrome (Fig. 5). Basic studies using canine ventricular tissue and cell preparations confirmed this possibility [25], which is also suspected by a case presenting de novo appearance of J waves without evidence of coronary spasm under the cumulative intracoronary application of ACh [39]. However, a prospective cohort of ACh application tests, widely conducted in catherization laboratories, is required to strengthen the conceptual framework (Fig. 5) regarding the hypothetical ACh challenge test of ERS.

Disclosures

Financial support

This report received no financial support.

Conflict of interest

All authors declare no conflict of interest related to this study.

Acknowledgments

We thank the staff in the Department of Medicine and Biosystemic Science of Kyushu University Graduate School of Medical Sciences (Fukuoka, Japan) for their enthusiastic cooperation with us in our work in the electrophysiology laboratory. We also thank Ms. Kanae Nagao for her secretarial assistance and Ms. Noriko Muta for her technical assistance.

References

[1] Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circ Res 1983;53:557–73.
[2] Yasue H, Horio Y, Nakamura N, et al. Induction of coronary artery spasm by acetylcholine in patients with variant angina. Possible role of parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 1986;74:935–62.
[3] Kuraishi K, Nishishashi T, Strandafi CC, et al. Diversity of endothelium-derived vasocontracting factors – arachidonic acid metabolites. Acta Pharmacol Sin 2003;24:1065–9.
[4] ECS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013): digest version. Circ J 2014;78:2779–801.
[5] Machida T, Hashimoto N, Kiihara I, et al. Effects of a highly selective acetylcholine-activated K⁺ channel blocker on experimental atrial fibrillation. Circ Arrhythm Electrophysiol 2011;4:94–102.
[6] Zhao QY, Huang CX, Liang J, et al. Effect of vagal stimulation and differential densities of M2 receptor and IK, ACh in canine atria. Int J Cardiol 2008;126:352–8.
[7] Sueda S, Kohno H. Overview of complications during pharmacological spasm provocation tests. J Cardiol 2016;68:1–6.
[8] Maruyama M, Aizawa Y, Sato M, et al. Tachycardia-dependent augmentation of Osborn waves associated with ventricular fibrillation in a patient with vasospastic angina. J Cardiovasc Electrophysiol 2002;13:486–9.
[9] Rikitpara S, Suresh S, Chandrasekhar M, et al. Occurrence of “J waves” in 12-lead ECG as a marker of acute ischemia and their cellular basis. Pacing Clin Electrophysiol 2007;30:817–9.
[10] Jastrzebski M, Kukla P. Ischemic J wave: novel risk marker for ventricular fibrillation? Heart Rhythm 2009;6:829–35.
[11] Yagihara N, Sato A, Furushima H, et al. Ischemia-induced prominent J wave in a patient with Brugada syndrome. Intern Med 2010;49:1979–82.
[12] Zhu D, Luo YM, A KH, et al. Vasospastic angina with J waves formation in patients with sudden loss of consciousness. J Geriatr Cardiol 2015;12:313–8.
[13] Janse MJ, Weil AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989;69:1049–169.
[14] Lukas A, Antzelevitch C. Differences in the electrophysiological response of canine ventricular epicardium and endocardium to ischemia: role of the transient outward current. Circulation 1993;88:2903–15.
[15] Di Diego JM, Antzelevitch C. Acute myocardial ischemia: cellular mechanisms underlying ST segment elevation. J Electrocardiol 2014;47:486–90.
[16] Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res 1988;62:116–26.
[17] Antzelevitch C. fish J. Electrical heterogeneity within the ventricular wall. Basic Res Cardiol 2001;96:517–27.
[18] Zicha S, Xiao L, Stafford S, et al. Transmural expression of transient outward potassium current subunits in normal and failing canine and human hearts. J Physiol 2004;561:735–48.
[19] Yan GX, Joshi A, Guo D, et al. Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. Circulation 2004;110:1036–41.
[20] Hiraoaka M. Pathophysiological functions of ATP-sensitive K⁺ channels in myocardial ischemia. Jpn J Physiol 1997;38:297–315.
[21] Di Diego JM, Antzelevitch C. Pinacidil-induced electrical heterogeneity and extrasystolic activity in canine ventricular tissues. Does activation of ATP-regulated potassium current promote phase 2 reentry? Circulation 1991;88:1177–89.
[22] Di Diego JM, Antzelevitch C. Ischemic ventricular arrhythmias experimental models and their clinical relevance. Heart Rhythm 2011;8:1193–8.
[23] Nakao K, Miyamoto Y. J wave is better left alone? Circ J 2015;79:2110–1.
[24] Haisaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 2008;358:2016–23.
[25] Antzelevitch C, Yan GX, Ackerman MJ, et al. J-wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge. J Arrhythm 2016;32:315–39.
[26] Aizawa Y, Sato M, Kitazawa H, et al. Tachycardia-dependent augmentation of “notched J waves” in a general patient population without ventricular fibrillation or cardiac arrest: not a repolarization but a depolarization abnormality? Heart Rhythm 2015;12:376–83.
Koncz I, Gurabi Z, Patocskai B, et al. Mechanisms underlying the development of the electrocardiographic and arrhythmic manifestations of early repolarization syndrome. J Mol Cell Cardiol 2014;68:20–8.

Brugada P, Brugada J. Right bundle branch block, persistent ST elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391–6.

Kawata H, Morita H, Yamada Y, et al. Prognostic significance of early repolarization in inferolateral leads in Brugada patients with documented ventricular fibrillation: a novel risk factor for Brugada syndrome with ventricular fibrillation. Heart Rhythm 2013;10:1161–8.

Kaneko Y, Horie M, Niwano S, et al. Electrical storm in patients with Brugada syndrome is associated with early repolarization. Circ Arrhythm Electrophysiol 2014;7:1122–8.

Conte G, de Asmundis C, Sieira J, et al. Prevalence and clinical impact of early repolarization pattern and QRS-fragmentation in high-risk patients with Brugada syndrome. Circ J 2016;80:2109–16.

Chinushi M, Furushima H, Tanabe Y, et al. Similarities between Brugada syndrome and ischemia-induced ST-segment elevation: clinical correlation and synergy. J Electrocardiol 2005;38:18–21.

Extramiana F, Setz J, Maison-Blanche P, et al. Quantitative assessment of ST segment elevation in Brugada patients. Heart rhythm 2006;3:1175–81.

Ikeda T, Abe A, Yasu S, et al. The full stomach test as a novel diagnostic technique for identifying patients at risk of Brugada syndrome. J Cardiovasc Electrophysiol 2006;17:602–7.

Nishizaki M, Sakurada H, Mizusawa Y, et al. Influence of meals on variations of ST segment elevation in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2008;19:62–8.

Arai M, Nakazawa K, Takagi A, et al. Brugada syndrome-like ST-segment elevation increase exacerbated by vomiting. Circ J 2004;68:712–4.

Miyazaki H, Nakagawa M, Shin Y, et al. Comparison of autonomic J-wave modulation in patients with idiopathic ventricular fibrillation and control subjects. Circ J 2013;77:330–7.

Shinohara T, Kondo H, Otsubo T. Exaggerated reactivity of parasympathetic nerves is involved in ventricular fibrillation in J-wave syndrome. J Cardiovasc Electrophysiol 2016. http://dx.doi.org/10.1111/jce.13135.

Hisamatsu T, Miura K, Okubo T, et al. (for the NIPPON DATA 80 Research Group). Interaction between dietary marine-derived n-3 fatty acids intake and J-point elevation on the risk of cardiac death: a 24-year follow-up of Japanese men. Heart 2013;99:1024–9.

Endo T, Tomita H, Higuma T, et al. Low serum eicosapentaenoic acid level is a risk for ventricular arrhythmia in patients with acute myocardial infarction: a possible link to J-waves. Heart Vessel 2014;29:847–54.

Kodama H, Fujita K, Moriyama S, et al. Manifestation of J Wave induced by acetylcholine applied for a coronary spasm provocation test in a patient with aborted sudden cardiac death. J Arrhythm 2016. http://dx.doi.org/10.1016/j.joa.2016.09.001.

Sato A, Tanabe Y, Chinushi M, et al. Analysis of J waves during myocardial ischemia. Europace 2012;14:715–23.

Kouni S, Wasserstrom JA. Acetylcholine-sensitive muscarinic K⁺ channels in mammalian ventricular myocytes. Am J Physiol 1994;266:H1812–21.

Baek YS, Park SD, Lee MJ, et al. Relationship between J wave and vagal activity in patients who do not have structural heart disease. Ann Noninvasive Electrocardiol 2015;20:464–73.

Hartzell HC, Fischmeister R. Opposite effects of cyclic GMP and cyclic AMP on Ca²⁺ current in single heart cells. Nature 1986;323:273–5.

Van GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999;100:1660–6.

Noda T, Shimizu W, Taguchi A, et al. ST-segment elevation and ventricular fibrillation without coronary spasm by intracoronary injection of acetylcholine and/or ergonovine maleate in patients with Brugada syndrome. J Am Coll Cardiol 2002;40:1841–7.